Published on Fri Aug 27 2021

Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.

Yan-Ting Chen, Erik T Valent, Erik H van Beers, Rowan Kuiper, Stefania Oliva, Torsten Haferlach, Wee-Joo Chng, Martin H van Vliet, Pieter Sonneveld, Alessandra Larocca

gene expression profiling (GEP) is studied in the context of clinical trials, for which 50%-80% of patients are not eligible. GEP analysis outside clinical trials aims to improve clinical risk assessment of multiple myeloma (MM) patients.

1
2
0
Abstract

Typically, prognostic capability of gene expression profiling (GEP) is studied in the context of clinical trials, for which 50%-80% of patients are not eligible, possibly limiting the generalizability of findings to routine practice. Here, we evaluate GEP analysis outside clinical trials, aiming to improve clinical risk assessment of multiple myeloma (MM) patients.